Overall market sentiment has been high on Equillium Inc (EQ) stock lately. EQ receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With EQ Stock Today?
Equillium Inc (EQ) stock is higher by 2.1% while the S&P 500 is lower by -0.34% as of 9:57 AM on Friday, Jan 22. EQ is higher by $0.12 from the previous closing price of $5.72 on volume of 113,919 shares. Over the past year the S&P 500 has risen 15.60% while EQ is higher by 41.06%. EQ lost -$1.56 per share in the over the last 12 months.
To screen for more stocks like Equillium Inc click here.
More About Equillium Inc
Equillium Inc is a biopharmaceutical company. It is developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Its primary product candidate is itolizumab, which targets the CD6-ALCAM signaling pathway, which helps in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab is the treatment for multiple severe immuno-inflammatory disorders, including graft versus host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.
Click Here to get the full Stock Score Report on Equillium Inc (EQ) Stock.
